Drug Profile


Alternative Names: pasireotide-LAR; Signifor; Signifor LAR; SOM-230; SOM-230-LAR; SOM230C

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Antineoplastics; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin-releasing factor antagonists; Growth hormone releasing factor antagonists; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary ACTH hypersecretion; Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pituitary ACTH hypersecretion
  • Registered Acromegaly
  • Phase III Pancreatic disorders
  • Phase II Cluster headache; Gastrointestinal disorders; Gigantism; Hepatocellular carcinoma; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
  • Phase I Gastrointestinal cancer; Malignant melanoma; Merkel cell carcinoma; Pancreatic cancer
  • Preclinical Radiation injuries
  • Discontinued Carcinoid tumour

Most Recent Events

  • 20 Jul 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval for Pituitary ACTH Hypersecretion in European Union
  • 10 Apr 2017 Novartis completes a phase II trial for Acromegaly and Gigantism in Japan (IM) (NCT01673646)
  • 10 Apr 2017 Novartis completes a phase III trial for Pituitary ACTH Hypersecretion in USA, Argentina, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Italy, Japan, Netherlands, Peru, Poland, Russia, Spain, Thailand, Turkey and United Kingdom (NCT01374906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top